

E-Filed

ORIGINAL

1 MAYER BROWN LLP
2 MICHAEL A. MOLANO (SBN171057)
3 mmolano@mayerbrown.com
4 Two Palo Alto Square, Suite 300
5 3000 El Camino Real
6 Palo Alto, CA 94306-2112
7 Telephone: (650) 331-2000
8 Facsimile: (650) 331-2060

9 LISA FERRI (to be admitted *pro hac vice*)
10 lferrri@mayerbrown.com
11 RICHARD MCCORMICK (to be admitted *pro hac vice*)
12 rmccormick@mayerbrown.com
13 1675 Broadway
14 New York, NY 10016-5820
15 Telephone: (212) 506-2500
16 Facsimile: (212) 262-1910

17 Attorneys for Plaintiff
18 BRISTOL-MYERS SQUIBB COMPANY

FILED
MAY - 3 2013
RICHARD W. WIEKING
CLERK, U.S. DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND
Fee Paid
ISS
14

ADR

19 UNITED STATES DISTRICT COURT
20 FOR THE NORTHERN DISTRICT OF CALIFORNIA

21 BRISTOL-MYERS SQUIBB COMPANY,
22 Plaintiff,
23 v.
24 GENENTECH, INC. and CITY OF HOPE,
25 Defendants.

26 CASE NO.
27 **13-2045**
28 COMPLAINT FOR DECLARATORY
JUDGMENT

DEMAND FOR JURY TRIAL

Plaintiff Bristol-Myers Squibb Company ("Bristol-Myers Squibb") for its Complaint against Genentech, Inc. ("Genentech") and City of Hope (collectively, "Defendants"), alleges as follows:

NATURE OF THE CASE

1. In this action, Bristol-Myers Squibb seek a declaration that U.S. Patent No. 6,331,415 entitled "Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein" (the "Cabilly II Patent," attached as Exhibit A), including the *Ex Parte* Reexamination Certificate issued pursuant to Reexamination Nos. 90/007,542 and 90/007,859

COMPLAINT FOR DECLARATORY JUDGMENT
CASE NO.: _____

1 (attached as Exhibit B), and U.S. Patent No. 7,923,221, entitled “Methods of Making Antibody
2 Heavy and Light Chains Having Specificity for a Desired Antigen” (the “Cabilly III Patent,”
3 attached as Exhibit C) are invalid and not infringed by the manufacture, use, sale, offer to sell, or
4 importation of: (1) Erbitux[®] (cetuximab), an antibody product that Bristol-Myers Squibb sells in
5 the United States pursuant to a commercial agreement with ImClone Systems LLC (“ImClone”),
6 a wholly owned subsidiary of Eli Lilly and Company (“Lilly”); and (2) Plaintiff’s Yervoy[®]
7 (ipilimumab) antibody product, which it manufactures and sells in the United States. (The
8 Cabilly II patent and Cabilly III patent are collectively referred to as the “Cabilly Patents.”)

9 2. Bristol-Myers Squibb brings this action to lift the cloud created by the imminent
10 threat of Defendants’ enforcement of the Cabilly Patents against Plaintiff. Without declaratory
11 relief, the threat of enforcement of the Cabilly Patents poses a substantial risk to Plaintiff as well
12 as to patients, nurses and doctors now using Erbitux and Yervoy. The continued existence and
13 enforcement of these patents impedes not only the development and sale of Erbitux and Yervoy,
14 but also the development and sale of other life-saving recombinant antibody products.

15 3. Defendants have asserted that the Cabilly Patents broadly cover the use of certain
16 well-known, conventional recombinant methods to produce any antibody product in any type of
17 host cell. For example, according to Sean Johnston, then Genentech’s Vice President of
18 Intellectual Property, “[t]he recently issued [Cabilly II] patent broadly covers the co-expression
19 of immunoglobulin heavy and light chain genes in a single host cell ... We do not believe that
20 the claims are limited by type of antibody (murine, humanized, or human) or by host cell type.”
21 See Debra Robertson, “Genentech Awarded Critical Antibody Patent,” *Nature Biotechnology*,
22 vol. 20, p. 108 (Feb. 2002) (attached as Exhibit D).

23 4. Defendants have filed multiple infringement claims under the Cabilly Patents
24 against companies who have made and sold antibody products that, on information and belief,
25 were produced using recombinant methods similar to the methods used to make Erbitux and
26 Yervoy.

27 5. In public statements, Genentech has specifically identified Erbitux as a potential
28 competitor to one of Genentech’s own antibody products, Avastin. See Genentech, Inc., 2008

1 10-K Annual Report (2-20-2009), retrieved from SEC EDGAR, at 13. On information and
2 belief, Genentech's pipeline antibody product MPDL3280A is presently in clinical trials to test
3 its safety and effectiveness for the treatment of melanoma, non-small-cell lung carcinoma and
4 renal cell carcinoma. These indications overlap with those for Plaintiff's Yervoy product, which
5 is approved by the FDA for melanoma.

6 6. Genentech has stated that it expects to be involved in future litigations relating to
7 the enforcement of the Cabilly II patent. *See* Genentech, Inc., 2008 10-K Annual Report (2-20-
8 2009), retrieved from SEC EDGAR, at 25, 39. The term of both of the Cabilly Patents expires in
9 December 2018.

10 7. Given Defendants' past acts and statements, as set forth in further detail below,
11 the manufacture and sale of Erbitux and Yervoy in the United States creates a real, immediate
12 and substantial dispute between the parties concerning the Cabilly Patents, for which Bristol-
13 Myers Squibb now seeks declaratory relief.

14 **PARTIES**

15 8. Bristol-Myers Squibb is a company organized and existing under the laws of the
16 State of Delaware, having its principal place of business at 345 Park Avenue, New York, New
17 York 10154. Bristol-Myers Squibb maintains a research and development facility in Redwood
18 City, California, that houses biologics drug discovery activities focused on antibody therapeutics.
19 Bristol-Myers Squibb employs over 150 scientists at its Redwood City facility.

20 9. On information and belief, Defendant Genentech, Inc. is a corporation duly
21 organized and existing under the laws of the State of Delaware, having its principal place of
22 business at 1 DNA Way, South San Francisco, California 94080-4990.

23 10. On information and belief, Defendant City of Hope is a California not-for-profit
24 organization duly organized and existing under the laws of the State of California, having its
25 principal place of business in Duarte, California. On information and belief, City of Hope has a
26 place of business in this District at 55 Hawthorne Street, Suite 450, San Francisco, California
27 94105.

28

1 11. On information and belief, Genentech and City of Hope are co-assignees of the
2 Cabilly Patents.

3 JURISDICTION AND VENUE

4 12. This action arises under the Declaratory Judgment Act of 1934 (28 U.S.C. §§
5 2201-2202), Title 28 of the United States Code, for the purposes of determining an actual and
6 justiciable controversy between the parties, and the patent laws of the United States, Title 35 of
7 the United States Code. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331
8 and 1338(a).

9 13. This Court has personal jurisdiction over Genentech based on its principal place
10 of business in California. This Court has personal jurisdiction over City of Hope based on its
11 organization under the laws of the State of California and because its principal place of operation
12 is in California.

13 14. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because both
14 Defendants reside in this District and because a substantial part of the events or omissions giving
15 rise to the claims occurred in this District.

16 INTRADISTRICT ASSIGNMENT

17 15. Pursuant to Civil L.R. 3-2(c), this intellectual property action shall be assigned on
18 a district-wide basis.

19 RELATED CASE

20 16. This action concerns substantially the same parties, property, transactions and/or
21 events as another action filed and presently pending in this District (Oakland Division), *Eli Lilly*
22 *and Company and ImClone Systems LLC v. Genentech, Inc. and City of Hope*, Case No. CV13-
23 0919 (YGR). There will therefore be an unduly burdensome duplication of labor and expense or
24 conflicting results if the cases are conducted before different Judges in this District.

25 THE CABILLY PATENTS

26 17. On April 8, 1983, Shmuel Cabilly, Herbert Heyneker, William Holmes, Arthur
27 Riggs, and Ronald Wetzel (collectively, the “Cabilly Applicants”) filed a patent application in
28 the United States Patent and Trademark Office (“PTO”) that issued on March 28, 1989, as U.S.



1 Patent No. 4,816,567 (the “Cabilly I Patent”). On its face, the Cabilly I Patent is assigned to
2 Genentech and, by certificate of correction, is also assigned to City of Hope. The Cabilly I
3 patent expired on March 28, 2006.

4 18. At the time the Cabilly I Patent issued, the Cabilly Applicants had a continuation
5 application pending in the PTO, which issued on December 18, 2001, as the Cabilly II Patent.
6 On its face, the Cabilly II Patent is assigned to Genentech and, by certificate of correction, is also
7 assigned to City of Hope.

8 19. At the time the Cabilly II Patent issued, the Cabilly Applicants had a continuation
9 application pending in the PTO, which issued on April 12, 2011, as the Cabilly III Patent. The
10 Cabilly III Patent is assigned to Genentech and City of Hope.

11 20. The Cabilly II Patent and Cabilly III Patent relate to recombinant techniques for
12 manufacturing antibody therapeutics. Both patents claim priority to the Cabilly I Patent
13 application, filed on April 8, 1983, in the early days of monoclonal antibodies.

14 21. The Cabilly II Patent was the subject of a nine-year patent interference and two
15 reexaminations. The Cabilly III Patent has also been through a patent interference.

16 22. The nine-year Cabilly II Patent interference caused the claims of the Cabilly II
17 Patent to have an effective patent life of 35 years after the date the Cabilly I Patent application
18 was filed, with an expiration date on December 18, 2018. The Cabilly III Patent is subject to a
19 terminal disclaimer, and thus the Cabilly III Patent claims will have the same expiration date as
20 the Cabilly II Patent claims.

21 **BRISTOL-MYERS SQUIBB’S AND LILLY’S ERBITUX®**

22 **(CETUXIMAB) PRODUCT**

23 23. Erbitux® (cetuximab) is a recombinant, mouse/human chimeric monoclonal
24 antibody that binds to the extracellular domain of human epidermal growth factor receptor
25 (“EGFR”). Erbitux was first approved by the FDA in 2004 for the treatment of colorectal cancer
26 and, in 2006, for the treatment of head and neck cancer.

27 24. Erbitux was initially developed by ImClone. Lilly, through its wholly owned
28 subsidiary ImClone, has a commercial agreement with Bristol-Myers Squibb relating to Erbitux.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.